Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel to Discuss 4th COVID Shot to Healthcare Providers: Health Minister
A Japanese health ministry panel on July 22 will consider the need for fourth COVID-19 jabs among healthcare and nursing care facility workers in view of the rapid spread in infections, with vaccinations set to proceed immediately once the specific…
To read the full story
Related Article
- Japan Begins Second COVID Booster for Age 60-Plus, High-Risk Adults
May 26, 2022
- Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
April 28, 2022
- Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
REGULATORY
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…